2018 Workshop on Free Energy Methods, Kinetics and Markov State Models in Drug Design

The 2018 Workshop on Free Energy Methods, Kinetics and Markov State Models in Drug Design

Dates and Locations

May 14th-18th, 2018

The Venue for May 14th
A reception will be held on Monday evening at Silicon Therapeutics

The Venue for Tuesday, May 15th through Friday, May 18th
The remainder of the meeting will be hosted at The Novartis Institutes for Biomedical Research, 220 Massachusetts Ave. Room 132, Cambridge, MA
On street metered parking is usually limited to two hours. There are public lots around the area. You can check public parking location and rates at http://en.parkopedia.com/parking/cambridge.
If you're coming via public transportation, take the subway red line to Kendall Square.

Sponsors and Social Media

We would like to thank the following sponsors:

Twitter hashtags: #drugalchemy #drugmsm; add #discuss if you have a discussion topic suggestion
Slack: https://alchemistry.slack.com

Introduction

This workshop focuses on free energy techniques—the latest innovations and use cases, force field parameterization as it touches these techniques, and sampling practices, among other things. We as organizers believe that these techniques are even closer than before to making an impact in appropriate drug discovery applications, by allowing physics-based prediction of physical properties such as binding affinity, selectivity, solubility, and membrane permeability. However, a number of challenges still remain. This workshop provides a unique opportunity to assess where we are today and what challenges must be tackled next to bring the potential of free energy techniques to bear on real-world applications. We also seek to identify particular problems in drug discovery where these methods can have an impact.

Our goal in this workshop is to bring together experts from pharma and supporting industries, as well as academia, in an intense and focused workshop to identify challenges and help chart the path forward. We are particularly interested in hearing about use cases, pitfalls and their solutions, and so on. We also firmly believe we can learn a great deal from failure, so we hope participants will go beyond just highlighting success stories to provide more detailed insight into successes and failures.

Organizers

• John Chodera, Memorial-Sloan Kettering Cancer Center (john.chodera@choderalab.org)
• Callum Dickson, Novartis (callum.dickson@novartis.com)
• Viktor Hornak, Novartis (viktor.hornak@novartis.com)
• John Manchester, Novartis, (john.manchester@novartis.com)
• David Mobley, University of California at Irvine (dmobley@uci.edu)
• Michael Schnieders, The University of Iowa (michael-schnieders@uiowa.edu)
• Jana Shen, The University of Maryland (Jana.Shen@rx.umaryland.edu)
• Woody Sherman, Silicon Therapeutics (woody@silicontx.com)

We also thank current advisors and previous organizers:

• Vijay Pande, Stanford University (pande@stanford.edu)
• Michael Shirts, University of Colorado Boulder (michael.shirts@colorado.edu)
• Camilo Velez-Vega, Entasis Therapeutics (camilo.velez@entasistx.com)